The COVID-19 Pandemic is a Global Public Health Priority
TOP THREE REGIONS WITH THE MOST REPORTED CASES:
1. Americas
2. Europe
3. South-East Asia
WHO August 2020
Global confirmed cases of COVID-19 have surpassed
23 million
WHO August 2020
An estimated 50-80% of COVID-19 cases are asymptomatic, and thus not likely to be diagnosed
Global Data Healthcare
In the USA, confirmed COVID-19 cases have reached
5 million
CDC August 2020
WHO August 2020
- Non-invasive
- Real-time results
- Quantifies levels of immunity and/or exposure (rather than just positive or negative result)
- Ability to be printed at scale, at a low cost
GBS Inc. has Collaborated with Harvard University to Develop a Real-time SARS-CoV-2 Antibody Biosensor
The Wyss Institute for Biologically Inspired Engineering at Harvard University is integrating our world-first Biosensor Platform technology with a specialised nanomaterial coating.
This gel-like coating allows the detection of IgM and/or igG antibodies which indicates a person’s current or previous exposure to the SARS-CoV-2 virus, and thus, a potential infection with COVID-19.
Further development could result in a chewing-gum sized diagnostic ‘strip’ to be used as a diagnostic tool for COVID-19 testing at point of care.